Validation of CP‐GEP (Merlin Assay) for predicting sentinel lymph node metastasis in primary cutaneous melanoma patients: A U.S. cohort study

BACKGROUND: Approximately 85% of melanoma patients who undergo a sentinel lymph node biopsy (SLNB) are node‐negative. Melanoma incidence is highest in patients ≥65 years, but their SLNB positivity rate is lower than in younger patients. CP‐GEP, a model combining clinicopathologic and gene expression...

Descripción completa

Detalles Bibliográficos
Autores principales: Yousaf, Ahmed, Tjien‐Fooh, Félicia J., Rentroia‐Pacheco, Barbara, Quattrocchi, Enrica, Kobic, Ajdin, Tempel, Dennie, Kolodney, Michael, Meves, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251603/
https://www.ncbi.nlm.nih.gov/pubmed/33914348
http://dx.doi.org/10.1111/ijd.15594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251603/
https://www.ncbi.nlm.nih.gov/pubmed/33914348
http://dx.doi.org/10.1111/ijd.15594

Ejemplares similares